期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 65, 期 13, 页码 8998-9010出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.2c00205
关键词
-
资金
- Intramural SISSA funding, Helmholtz Partnering Project on Innovative high-performance computing approaches for molecular neuromedicine
This study proposes a new drug strategy for the treatment of prion diseases by clearing prions. The researchers have identified a small molecule that inhibits SERPINA3/SerpinA3n, effectively reducing prion load in infected cells.
Prion diseases are a group of neurodegenerative disorders characterized by the accumulation of misfolded prion protein (called PrPSc). Although conversion of the cellular prion protein (PrPC) to PrPSc is still not completely understood, most of the therapies developed until now are based on blocking this process. Here, we propose a new drug strategy aimed at clearing prions without any direct interaction with neither PrPC nor PrPSc. Starting from the recent discovery of SERPINA3/SerpinA3n upregulation during prion diseases, we have identified a small molecule, named compound 5 (ARN1468), inhibiting the function of these serpins and effectively reducing prion load in chronically infected cells. Although the low bioavailability of this compound does not allow in vivo studies in prion-infected mice, our strategy emerges as a novel and effective approach to the treatment of prion disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据